Nature Communications (Nov 2018)

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets

  • Bieke Decaesteker,
  • Geertrui Denecker,
  • Christophe Van Neste,
  • Emmy M. Dolman,
  • Wouter Van Loocke,
  • Moritz Gartlgruber,
  • Carolina Nunes,
  • Fanny De Vloed,
  • Pauline Depuydt,
  • Karen Verboom,
  • Dries Rombaut,
  • Siebe Loontiens,
  • Jolien De Wyn,
  • Waleed M. Kholosy,
  • Bianca Koopmans,
  • Anke H. W. Essing,
  • Carl Herrmann,
  • Daniel Dreidax,
  • Kaat Durinck,
  • Dieter Deforce,
  • Filip Van Nieuwerburgh,
  • Anton Henssen,
  • Rogier Versteeg,
  • Valentina Boeva,
  • Gudrun Schleiermacher,
  • Johan van Nes,
  • Pieter Mestdagh,
  • Suzanne Vanhauwaert,
  • Johannes H. Schulte,
  • Frank Westermann,
  • Jan J. Molenaar,
  • Katleen De Preter,
  • Frank Speleman

DOI
https://doi.org/10.1038/s41467-018-06699-9
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 17

Abstract

Read online

In high-risk neuroblastoma cases, gains in chromosome 17q are common. Here, the authors investigate the epigenomics and transcriptomics of neuroblastoma, identifying TBX2 as a core regulatory circuitry component enhancing the reactivation of DREAM targets by MYCN/FOXM1.